Introduction:
Anemia is a common complication among patients with CKD and is multifactorial ,one of the factor is iron deficiency. Either oral or iv iron is recommended in CKD patients not on dialysis (CKD-ND).The optimal intravenous (IV) iron is the one which would allow rapid and safe correction of iron deficiency with a single infusion . This study evaluated the safety and efficacy of iron isomaltoside (IIM) in patients of non-dialysis-dependent CKD patients(CKD-ND) with iron deficiency anemia
Methods:
In this study ,100 patients of CKD-ND with iron deficiency anemia were taken and divided into 2 groups (group A and group B ) .Group A was given single dose of 1000 mg IIM and Group B was given Iron sucrose, 1000 mg ( administered as 5 doses of 200 mg IV injections over a 2-week period). All the patients were evaluated for serious or severe hypersensitivity reactions and change in haemoglobin (Hb),transferrin saturation (TSAT) and serum ferritin from baseline to Week 8.
Results:
A total of 100 patients were taken . The study showed no significant difference in the incidence of serious hypersensitivity reactions in both the groups . IIM led to a more pronounced increase in Hb at 2 ,4 and 8 weeks as compared to IS . IIM group showed a significant rise in TSAT over IS group at week 4 and week8 , but showed non inferiority at week 2.In terms of rise in ferritin IIM group showed superiorty over IS group at week 4 and week 8 .
Conclusions:
A single dose of IIM showed a better 8-week haematological response (in terms of Hb ,TSAT and serum ferritin ) as compared to multiple doses of IS and also showed low rates of hypersensitivity reactions .
I have no potential conflict of interest to disclose.
I did not use generative AI and AI-assisted technologies in the writing process.